https://www.thepharmaletter.com/article/takeda-oncology-pipeline-shifts-in-focus
Takeda oncology pipeline shifts in focus
23-02-2024
Japan’s largest drugmaker Takeda (TYO: 4502) decided to discontinue the development programs of its
four oncology assets - Phase III asset modakafusp alfa (TAK-573) and three Phase I chimeric antigen
receptor (CAR-T) assets: TAK-102, TAK-103 and TAK-940 - as part of a plan to align its focus on advancing
allogeneic cell therapies.
- Forums
- ASX - By Stock
- MSB
- Cell Therapy News/Articles
Cell Therapy News/Articles, page-17512
-
- There are more pages in this discussion • 309 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B |
Open | High | Low | Value | Volume |
$1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | $1.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.19 | 75212 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | 1.185 |
4 | 69624 | 1.180 |
3 | 122218 | 1.175 |
3 | 86297 | 1.170 |
2 | 52098 | 1.165 |
Price($) | Vol. | No. |
---|---|---|
1.190 | 75212 | 5 |
1.195 | 71199 | 8 |
1.200 | 793756 | 45 |
1.205 | 83717 | 4 |
1.210 | 193114 | 8 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |